Quick Answer
AIM ImmunoTech Inc. reported Cash and Equivalents of $2.98 million for fiscal year 2025.
AIM ImmunoTech Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.98M | +75.5% |
| 2024 | $1.70M | -68.7% |
| 2023 | $5.44M | -79.9% |
| 2022 | $27.05M | -15.7% |
| 2021 | $32.09M | -16.6% |
| 2020 | $38.50M | +2519.1% |
| 2019 | $1.47M | +391.6% |
| 2018 | $299.0K | -78.8% |
| 2017 | $1.41M | -41.4% |
| 2016 | $2.41M | +13.9% |
| 2015 | $2.12M | -1.9% |
| 2014 | $2.16M | +168.5% |
| 2013 | $803.0K | -63.7% |
| 2012 | $2.21M | -28.7% |
| 2011 | $3.10M | +6.3% |
| 2010 | $2.92M | -95.0% |
| 2009 | $58.07M | +849.0% |
| 2008 | $6.12M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.35M | +156.5% | +393.1% |
| June 30, 2025 | $476.0K | -86.6% | -47.0% |
| March 31, 2025 | $898.0K | -72.7% | -47.2% |
| December 31, 2024 | $1.70M | -68.7% | +85.9% |
| September 30, 2024 | $915.0K | -94.0% | -74.3% |
| June 30, 2024 | $3.55M | -83.1% | +7.9% |
| March 31, 2024 | $3.29M | -85.9% | -39.4% |
| December 31, 2023 | $5.44M | -79.9% | -64.4% |
- AIM ImmunoTech Inc. showed an increase of +75.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, AIM ImmunoTech Inc.’s cash and equivalents has declined by 51.2% (from $6.12 million to $2.98 million).
- The most recent figure is from AIM ImmunoTech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: